	US 12,403,157 B2
	System and method to reduce tissue ororgan adhesion
Matthew B. Dowling, Riverdale, MD (US)
Assigned to Medcura, Inc., Riverdale, MD (US)
Appl. No. 17/436,597
Filed by Medcura, Inc., Riverdale, MD (US)
PCT Filed Mar. 4, 2020, PCT No. PCT/US2020/021039 § 371(c)(1), (2) Date Sep. 4, 2021, PCT Pub. No. WO2020/181015, PCT Pub. Date Sep. 10, 2020.
Claims priority of provisional application 62/814,265, filed on Mar. 5, 2019.
Prior Publication US 2022/0168334 A1, Jun. 2, 2022
Int. Cl. A61K 31/727 (2006.01); A61K 31/722 (2006.01); A61L 31/04 (2006.01); A61L 31/06 (2006.01); A61L 31/14 (2006.01); A61L 31/16 (2006.01)

CPC A61K 31/722 (2013.01) [A61L 31/042 (2013.01); A61L 31/06 (2013.01); A61L 31/146 (2013.01); A61L 31/148 (2013.01); A61L 31/16 (2013.01); A61L 2300/404 (2013.01); A61L 2400/06 (2013.01)]

14 Claims

1. A method for reducing adhesion between organs and tissues, comprising:

applying a flowable solution of a hydrophobically-modified chitosan, wherein hydrophobic modifications of chitosan are selected to allow for adherence to tissue, cohesiveness of the composition upon application to tissue, and degradation after application; wherein the hydrophobically-modified chitosan is applied to surfaces of tissues or organs within a surgical site either before, during, and/or after a surgical procedure, wherein the hydrophobically-modified chitosan reduces adhesion between organs or tissues after surgery; and wherein the hydrophobically modified chitosan has about 10% to 50% of available functional groups occupied by hydrophobic groups, and wherein the hydrophobic groups comprise a C1 to C4 hydrocarbon group and a hydrocarbon group of greater than C6.